KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Amortization of Deferred Charges: 2009-2020

Historic Amortization of Deferred Charges for Novavax (NVAX) over the last 6 years, with Dec 2020 value amounting to $356,000.

  • Novavax's Amortization of Deferred Charges changed negligibly% to $356,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $1.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.4 million for FY2020, which is negligibly% changed negligibly from last year.
  • Per Novavax's latest filing, its Amortization of Deferred Charges stood at $356,000 for Q4 2020, which was down 0.00% from $356,000 recorded in Q3 2020.
  • Over the past 5 years, Novavax's Amortization of Deferred Charges peaked at $357,000 during Q4 2017, and registered a low of $237,000 during Q1 2016.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $356,000 (2020), whereas its average is $356,000.
  • Per our database at Business Quant, Novavax's Amortization of Deferred Charges surged by 50.21% in 2017 and then decreased by 0.28% in 2018.
  • Novavax's Amortization of Deferred Charges (Quarterly) stood at $356,000 in 2016, then rose by 0.28% to $357,000 in 2017, then dropped by 0.28% to $356,000 in 2018, then remained steady at $356,000 in 2019, then remained steady at $356,000 in 2020.
  • Its Amortization of Deferred Charges was $356,000 in Q4 2020, compared to $356,000 in Q3 2020 and $356,000 in Q2 2020.